

IPERION LIMITED

Results for announcement to the market		
Name of issuer	Iperion Limited (NZX: IPR)	
Reporting Period	12 months to 31 March 2025	
Previous Reporting Period	12 months to 31 March 2024	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$0	0%
Total Revenue	\$0	0%
Net profit/(loss) from continuing operations	\$(444)	(46%)
Total net profit/(loss)	\$(444)	(46%)
Interim/Final Dividend		
Amount per Quoted Equity Security	The company does not propose to pay a dividend at this time.	
Imputed amount per Quoted Equity Security	Not applicable	
Record Date	Not applicable	
Dividend Payment Date	Not applicable	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.001	\$0.002
A brief explanation of any of the figures above necessary to enable the figures to be understood	Included with this report is the commentary from the Directors and financial statements for the year ended 31 March 2025. The financial statements are in the process of being audited.	
Authority for this announcement		
Name of person authorised to make this announcement	John Cilliers	
Contact person for this announcement	John Cilliers	
Contact phone number	+6 27 242 8485	
Contact email address	john.cilliers@outlook.co.nz	
Date of release through MAP	29 May 2025	

IPERION LIMITED

Preliminary Full Year Result for the Year Ended 31 March 2025.

Dear Shareholders

The Directors of Iperion Limited (“the Company”) are pleased to report its financial results for the year ended 31 March 2025.

Financial Results

The Company reported a net loss attributable to shareholders of \$444,433 for the year. This compares with a net loss attributable to shareholders of \$822,259 for the previous year.

The manufacturing plant expense for the year was \$150,000. This is significantly less than the \$500,000 incurred in the prior year. The prior year consisted of \$100,000 for the establishment of the manufacturing facility and \$400,000 for the fixed annual facility and operating fees. The Company received a discount of \$350,000 on the fixed fee for the 2025 year in recognition of lower than expected production activity and the plant being partially supported by research grants secured by the Operator, Three Summit Ventures, on the ongoing development in applications for the *Pathoglaze*[®] product.

Three Summit Ventures has also agreed to fully discount the agreed \$400,000 fixed fee for the next financial year ending March 2026. Fees required to support direct production costs may still be payable when sales activities commence.

Administrative expenses for the year were \$306,531 decreasing by \$47,841 on the prior year. Expenses remained mostly in line with the previous year, except for stock exchange costs that were lower this year and the previous year included higher costs for international trade fairs.

Operations

Operations continue to be focused on completing product trials applying *Pathoglaze* in various applications, undertaken in response to and in collaboration with potential large multinational commercial customers interested in applying *Pathoglaze* in their own products manufacturing processes. Possible applications for *Pathoglaze* previously successfully tested, includes antimicrobial coatings for furniture and egg cartons, kitchen chopping boards, applied to textiles to make odour combating clothing, or mixed in plastics used in the automotive industry or in food containers to make them antimicrobial and as a coating on curtains to reduce microbes in hospitals. Recent trials completed include manufacture of bags used in shipping cocoa and coffee beans, reducing microbial contamination and associated losses incurred during transport, providing a new alternative to the standard bags currently used in these industries.

The Company continues to work toward securing long term sales agreements.

Having completed various product trials the focus of the company is on marketing activities and converting the product trials undertaken with potential customers into long term sales agreements. Based on approved base case forecasts with no sales, the Company has sufficient cash reserves to cover its costs over the next 12 months.

On behalf of the Directors of Iperion the Company extends its thanks to the shareholders for their support of the Company.

Preliminary Statement of Comprehensive Income

For the year ended 31 March 2025

	Unaudited Year 2025 \$	Audited Year 2024 \$
Outsourced manufacturing plant expenses	(150,000)	(500,000)
Interest Income - financial asset at amortised cost	20,382	41,396
Administrative expenses	(306,531)	(354,372)
Depreciation, amortisation and impairment	(8,284)	(9,283)
Loss before interest and tax	(444,433)	(822,259)
Finance costs	-	-
Loss before income tax	(444,433)	(822,259)
Income tax expense	-	-
Net loss for the period attributable to shareholders	(444,433)	(822,259)
Other comprehensive income	-	-
Total comprehensive loss for the period attributable to shareholders	(444,433)	(822,259)

Preliminary Statement of Financial Position

As at 31 March 2025

	Unaudited Year 2025 \$	Audited Year 2024 \$
Assets		
Current assets		
Cash and cash equivalents	425,341	168,647
Term Deposit	-	697,834
GST receivable	1,384	-
Income tax receivable (RWT)	7,563	12,030
	434,288	878,511
Non-current assets		
NZX Deposit	20,000	20,000
	20,000	20,000
Total assets	454,288	898,511
Equity and liabilities		
Current liabilities		
Trade and other payables	94,640	93,105
GST payable	-	1,325
Total liabilities	94,640	94,430
Equity		
Issued capital	5,672,856	5,672,856
Accumulated loss	(5,313,208)	(4,868,775)
Total equity	359,648	804,081
Total equity and liabilities	454,288	898,511

Preliminary Statement of Changes in Equity

For the year ended 31 March 2025

	Unaudited		
	Issued capital	Accumulated Loss	Total equity
	\$	\$	\$
As at 1 April 2024	5,672,856	(4,868,775)	804,081
Loss for the year	-	(444,433)	(444,433)
Total comprehensive income	-	(444,433)	(444,433)
At 31 March 2025	5,672,856	(5,313,208)	359,648
As at 1 April 2023	5,672,856	(4,046,516)	1,626,340
Loss for the year	-	(822,259)	(822,259)
Total comprehensive income	-	(822,259)	(822,259)
At 31 March 2024	5,672,856	(4,868,775)	804,081

Preliminary Statement of Cash Flows

For the year ended 31 March 2025

	Unaudited Year 2025 \$	Audted Year 2024 \$
Operating activities		
Interest received	13,622	41,479
Payments to suppliers	(479,839)	(782,103)
Net GST refunds received	22,134	22,134
Income tax paid	(7,563)	(12,030)
Income tax refund received	12,030	5,766
Net cash flows from operating activities	(439,616)	(724,754)
Investing activities		
Purchase of intangible assets	(8,284)	(9,283)
Cash received from maturity of term deposit	704,594	520,571
Net cash flows from investing activities	696,310	511,288
Net increase / (decrease) in cash and cash equivalents	256,694	(213,466)
Cash and cash equivalents at beginning of year	168,647	382,113
Cash and cash equivalents at end of year	425,341	168,647